{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:55:24Z","timestamp":1791248124435,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,6,25]],"date-time":"2007-06-25T00:00:00Z","timestamp":1182729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the polymorphisms of several genes involved in the azathioprine and mercaptopurine metabolism, in an attempt to explain their toxicity and efficacy in Crohn\u2019s disease and ulcerative colitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In 422 consecutive patients (250 with Crohn\u2019s disease and 172 with ulcerative colitis) and 245 healthy controls, single nucleotide polymorphisms of thiopurine methyltransferase, inosine triphosphate pyrophosphatase and hypoxanthine phosphoribosyl transferase (HPRT1) genes were related to the occurrence of adverse drug reactions (ADRs) and efficacy of therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy\u2010three patients reported 81 episodes of ADRs; 45 patients did not respond to therapy. Frequency of thiopurine methyltransferase risk haplotypes was significantly increased in patients with leucopenia (26% vs. 5.7% in patients without ADRs, and 4% of controls) (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001); no correlation with other ADRs and efficacy of therapy was found. Conversely, the frequency of inosine triphosphate pyrophosphatase and HPRT1 risk genotypes was not significantly different in patients with ADRs (included leucopenia). Non\u2010responders had an increased frequency of inosine triphosphate pyrophosphatase risk genotypes (<jats:italic>P<\/jats:italic>\u2003=\u20030.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The majority of azathioprine\/mercaptopurine\u2010induced ADRs and efficacy of therapy are not explained by the investigated gene polymorphisms. The combined evaluation of all three genes enhanced the correlation with leucopenia (43.5% vs. 23% in controls) (<jats:italic>P<\/jats:italic>\u2003=\u20030.008), at the expense of a reduced accuracy (60%).<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2007.03421.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T12:35:43Z","timestamp":1279888543000},"page":"737-745","source":"Crossref","is-referenced-by-count":41,"title":["Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy"],"prefix":"10.1111","volume":"26","author":[{"given":"O.","family":"PALMIERI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"LATIANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"BOSSA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"VECCHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"D\u2019INC\u00c0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"GUAGNOZZI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"TONELLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"CUCCHIARA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"VALVANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"LATIANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"ANDRIULLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"ANNESE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.2.143"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.4.485"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200404000-00018"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/14622416.3.1.89"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200402001-00008"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2005.10.003"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70140-5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200403000-00006"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.057158"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20377"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200027639"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2005.10.019"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200411000-00010"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.055947"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.10217"},{"key":"e_1_2_6_17_2","first-page":"2537","volume-title":"The Metabolic and Molecular Basis of Inherited Disease","author":"Jinnah HA","year":"2001"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020831"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02701.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.01.047"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.8.1081"},{"key":"e_1_2_6_22_2","volume-title":"Molecular Cloning: A Laboratory Manual","author":"Sambrook J","year":"1989"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000246"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/clinchem\/47.3.548","article-title":"High\u2010throughput genotyping of thiopurine S\u2010methyltransferase by denaturing HPLC","volume":"47","author":"Schaeffeler E","year":"2001","journal-title":"Clin Chem"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502352102"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000174788.69991.6b"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209372"},{"key":"e_1_2_6_28_2","first-page":"1137","volume":"23","author":"De Ridder L","year":"2006","journal-title":"Pharmacogenetics of thiopurine therapy in paediatric IBD patients"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074930"},{"key":"e_1_2_6_30_2","first-page":"1664","article-title":"ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients","volume":"54","author":"Van Dieren JM","year":"2005","journal-title":"Gut"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01690.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200208000-00003"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70354-4"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00843.x"},{"key":"e_1_2_6_35_2","volume-title":"Package insert for azathioprine\/6\u2010mercaptopurine","year":"2005"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02124.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41900.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1155\/2005\/470863","article-title":"Thiopurine methyltransferase activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events","volume":"19","author":"Sayani FA","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200624080-00004"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03421.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03421.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:02:38Z","timestamp":1697234558000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03421.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,25]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03421.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03421.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,25]]}}}